Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Morphic Holding Inc (MORF)

Morphic Holding Inc (MORF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,082,743
  • Shares Outstanding, K 38,477
  • Annual Sales, $ 19,790 K
  • Annual Income, $ -95,540 K
  • 60-Month Beta 1.33
  • Price/Sales 55.01
  • Price/Cash Flow N/A
  • Price/Book 2.79
Trade MORF with:

Options Overview Details

View History
  • Implied Volatility 83.10% ( +9.68%)
  • Historical Volatility 56.65%
  • IV Percentile 58%
  • IV Rank 18.50%
  • IV High 240.13% on 07/26/22
  • IV Low 47.45% on 12/16/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 1
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 168
  • Open Int (30-Day) 164

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.80
  • Number of Estimates 4
  • High Estimate -0.76
  • Low Estimate -0.87
  • Prior Year -0.69
  • Growth Rate Est. (year over year) -15.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.08 +14.25%
on 09/26/22
30.40 -5.74%
on 09/08/22
+0.33 (+1.15%)
since 09/02/22
3-Month
21.62 +32.54%
on 07/05/22
33.77 -15.15%
on 08/16/22
+6.43 (+28.90%)
since 07/01/22
52-Week
19.23 +49.01%
on 06/13/22
68.75 -58.32%
on 11/05/21
-24.28 (-45.87%)
since 10/04/21

Most Recent Stories

More News
BioMarin (BMRN) Refiles BLA With FDA for Hemophilia Gene Therapy

If approved, BioMarin's (BMRN) valoctocogene roxaparvovec will be the first gene therapy for hemophilia A in the United States. The FDA filing also incorporates BMRN's responses to the CRL issued to the...

SNY : 40.07 (+2.25%)
BMRN : 86.52 (-0.21%)
SESN : 0.4843 (+7.62%)
MORF : 28.47 (+1.17%)
Sarepta (SRPT) Seeks FDA Nod for DMD Gene Therapy Candidate

If approved, Sarepta's (SRPT) SRP-9001 will be the first gene therapy for DMD indication in the United States. The company seeks approval for gene therapy under the accelerated pathway.

SNY : 40.07 (+2.25%)
RHHBY : 42.2900 (+4.50%)
SRPT : 109.07 (-0.79%)
MORF : 28.47 (+1.17%)
EMA Accepts Moderna's (MRNA) Filing for Omicron BA.4, BA.5 Booster

The EMA accepts Moderna's (MRNA) regulatory filing seeking authorization for bivalent COVID-19 booster vaccine, mRNA-1273.222, designed to target the Omicron BA.4 and BA.5 subvariants.

PFE : 44.54 (+0.91%)
MRNA : 125.80 (+3.98%)
MORF : 28.47 (+1.17%)
BNTX : 138.00 (+0.97%)
Pfizer (PFE), BNTX Seek EU Nod for Omicron Booster in Kids

Pfizer (PFE) and BioNTech seek to expand the EU label of their Omicron BA.4/BA.5-adapting bivalent COVID vaccine for children. It is already authorized for use in adolescents and adults.

PFE : 44.54 (+0.91%)
MRNA : 125.80 (+3.98%)
MORF : 28.47 (+1.17%)
BNTX : 138.00 (+0.97%)
Morphic Holding, Inc. (MORF) Moves 7.3% Higher: Will This Strength Last?

Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near...

MORF : 28.47 (+1.17%)
SRNE : 1.6050 (+3.55%)
Vertex (VRTX), CRISPR to Seek FDA Nod for Hemoglobinopathy Therapy

Vertex (VRTX) and partner CRISPR intend to start a rolling BLA submission with the FDA for their gene therapy in thalassemia and sickle cell disease indications by November 2022.

SNY : 40.07 (+2.25%)
VRTX : 297.64 (+0.07%)
CRSP : 65.00 (+3.01%)
MORF : 28.47 (+1.17%)
Pfizer (PFE) Seeks FDA Approval for Omicron Booster in Kids

Pfizer (PFE) and partner BioNTech seek authorization from the FDA for using their bivalent COVID-19 booster vaccine in kids. The vaccine is already authorized for use in adolescents and adults.

PFE : 44.54 (+0.91%)
MRNA : 125.80 (+3.98%)
MORF : 28.47 (+1.17%)
BNTX : 138.00 (+0.97%)
Valneva (VALN) Stock Down 66% in the Past 6 Months: Here's Why

Valneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance purchase agreement jeopardizes its COVID-19 vaccine program.

AZN : 57.01 (+2.63%)
PFE : 44.54 (+0.91%)
MORF : 28.47 (+1.17%)
VALN : 11.20 (+7.90%)
AstraZeneca's (AZN) Ultomiris Gets EC Nod for New Indication

AstraZeneca's (AZN) Ultomiris becomes the first and only long-acting C5 inhibitor to be approved for gMG in Europe.

SNY : 40.07 (+2.25%)
AZN : 57.01 (+2.63%)
AGEN : 2.11 (+0.96%)
MORF : 28.47 (+1.17%)
Merck's (MRK) Stock Up on Januvia Patent Win Against Viatris

Merck (MRK) gets a favorable ruling from a district court of West Virginia in two patents related to Januvia/Janumet against Viatris, which is looking to market its generic versions of the medicines in...

MRK : 88.44 (+1.02%)
AGEN : 2.11 (+0.96%)
MORF : 28.47 (+1.17%)
VTRS : 9.09 (+4.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Morphic Holding Inc. is a biopharmaceutical company. It focuses on the discovery and development of oral small-molecule integrin therapeutics for autoimmune, cardiovascular and metabolic diseases, as well as fibrosis and cancer. Morphic Holding Inc. is based in Waltham, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 30.48
2nd Resistance Point 29.70
1st Resistance Point 28.92
Last Price 28.47
1st Support Level 27.36
2nd Support Level 26.58
3rd Support Level 25.80

See More

52-Week High 68.75
Fibonacci 61.8% 49.83
Fibonacci 50% 43.99
Fibonacci 38.2% 38.15
Last Price 28.47
52-Week Low 19.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar